These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 37599441)
21. Engineered human IgG antibodies with longer serum half-lives in primates. Hinton PR; Johlfs MG; Xiong JM; Hanestad K; Ong KC; Bullock C; Keller S; Tang MT; Tso JY; Vásquez M; Tsurushita N J Biol Chem; 2004 Feb; 279(8):6213-6. PubMed ID: 14699147 [TBL] [Abstract][Full Text] [Related]
22. Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody. Schlein E; Andersson KG; Dallas T; Syvänen S; Sehlin D MAbs; 2024; 16(1):2339337. PubMed ID: 38634473 [TBL] [Abstract][Full Text] [Related]
23. Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies. Aertker KMJ; Pilvankar MR; Prass TM; Blech M; Higel F; Kasturirangan S MAbs; 2024; 16(1):2318817. PubMed ID: 38444390 [TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Wroblewski VJ J Biol Chem; 2007 Jan; 282(3):1709-17. PubMed ID: 17135257 [TBL] [Abstract][Full Text] [Related]
25. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A MAbs; 2015; 7(2):331-43. PubMed ID: 25658443 [TBL] [Abstract][Full Text] [Related]
26. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Proetzel G; Roopenian DC Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339 [TBL] [Abstract][Full Text] [Related]
27. Conformational Destabilization of Immunoglobulin G Increases the Low pH Binding Affinity with the Neonatal Fc Receptor. Walters BT; Jensen PF; Larraillet V; Lin K; Patapoff T; Schlothauer T; Rand KD; Zhang J J Biol Chem; 2016 Jan; 291(4):1817-1825. PubMed ID: 26627822 [TBL] [Abstract][Full Text] [Related]
28. Methods for Functional Characterization of FcRn Interactions with Therapeutic Antibodies and Fc-Fusion Proteins. Chung S; Lin YL; Nguyen V; Liu C Methods Mol Biol; 2022; 2313():295-303. PubMed ID: 34478146 [TBL] [Abstract][Full Text] [Related]
29. Fc Engineering: Tailored Synthetic Human IgG1-Fc Repertoire for High-Affinity Interaction with FcRn at pH 6.0. Saxena A; Bai B; Hou SC; Jiang L; Ying T; Miersch S; Sidhu SS; Wu D Methods Mol Biol; 2018; 1827():399-417. PubMed ID: 30196509 [TBL] [Abstract][Full Text] [Related]
30. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life. Mackness BC; Jaworski JA; Boudanova E; Park A; Valente D; Mauriac C; Pasquier O; Schmidt T; Kabiri M; Kandira A; Radošević K; Qiu H MAbs; 2019 Oct; 11(7):1276-1288. PubMed ID: 31216930 [TBL] [Abstract][Full Text] [Related]
31. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics. Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837 [TBL] [Abstract][Full Text] [Related]
32. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Datta-Mannan A; Chow CK; Dickinson C; Driver D; Lu J; Witcher DR; Wroblewski VJ Drug Metab Dispos; 2012 Aug; 40(8):1545-55. PubMed ID: 22584253 [TBL] [Abstract][Full Text] [Related]
33. Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry. Jensen PF; Larraillet V; Schlothauer T; Kettenberger H; Hilger M; Rand KD Mol Cell Proteomics; 2015 Jan; 14(1):148-61. PubMed ID: 25378534 [TBL] [Abstract][Full Text] [Related]
34. FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions. Challa DK; Velmurugan R; Ober RJ; Sally Ward E Curr Top Microbiol Immunol; 2014; 382():249-72. PubMed ID: 25116104 [TBL] [Abstract][Full Text] [Related]
35. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering. Wang Y; Tian Z; Thirumalai D; Zhang X J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896 [TBL] [Abstract][Full Text] [Related]
36. Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization. Foss S; Grevys A; Sand KMK; Bern M; Blundell P; Michaelsen TE; Pleass RJ; Sandlie I; Andersen JT J Control Release; 2016 Feb; 223():42-52. PubMed ID: 26718855 [TBL] [Abstract][Full Text] [Related]
37. Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey. Ng CM; Fielder PJ; Jin J; Deng R AAPS J; 2016 Jul; 18(4):948-59. PubMed ID: 27075465 [TBL] [Abstract][Full Text] [Related]
38. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Gurbaxani B; Dela Cruz LL; Chintalacharuvu K; Morrison SL Mol Immunol; 2006 Mar; 43(9):1462-73. PubMed ID: 16139891 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of an FcRn affinity chromatographic method for IgG1-type antibodies and evaluation of IgG variants. Cymer F; Schlothauer T; Knaupp A; Beck H Bioanalysis; 2017 Sep; 9(17):1305-1317. PubMed ID: 28901177 [TBL] [Abstract][Full Text] [Related]
40. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution. Pollastrini J; Dillon TM; Bondarenko P; Chou RY Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]